Cited by 67Pain Mechanisms and TreatmentsCannabis and Cannabinoid ResearchPain Management and Treatment

The effect of the palmitoylethanolamide analogue, palmitoylallylamide (L-29) on pain behaviour in rodent models of neuropathy

Open access
Wallace, V C J, Segerdahl, A R, Lambert, D M, Vandevoorde, S, Blackbeard, J, Pheby, T, Hasnie, F, Rice, A S C·2007·British Journal of Pharmacology

Abstract

BACKGROUND AND PURPOSE: Cannabinoids are associated with analgesia in acute and chronic pain states. A spectrum of central cannabinoid (CB(1)) receptor-mediated motor and psychotropic side effects limit their therapeutic potential. Here, we investigate the analgesic effect of the palmitoylethanolamide (PEA) analogue, palmitoylallylamide (L-29), which via inhibition of fatty acid amide hydrolase (FAAH) may potentiate endocannabinoids thereby avoiding psychotropic side effects. EXPERIMENTAL APPROACH: The in vivo analysis of the effect of L-29 on measures of pain behaviour in three rat models of neuropathic pain. KEY RESULTS: Systemically administered L-29 (10 mg kg(-1)) reduced hypersensitivity to mechanical and thermal stimuli in the partial sciatic nerve injury (PSNI) model of neuropathic pain; and mechanical hypersensitivity in a model of antiretroviral (ddC)-associated hypersensitivity and a model of varicella zoster virus (VZV)-associated hypersensitivity. The effects of L-29 were comparable to those of gabapentin (50 mg kg(-1)). The CB(1) receptor antagonist SR141716a (1 mg kg(-1)) and the CB(2) receptor antagonist SR144528 (1 mg kg(-1)) reduced the effect of L-29 on hypersensitivity in the PSNI and ddC models, but not in the VZV model. The peroxisome proliferator-activated receptor-alpha antagonist, MK-886 (1 mg kg(-1)), partially attenuated the effect of L-29 on hypersensitivity in the PSNI model. L-29 (10 mg kg(-1)) significantly attenuated thigmotactic behaviour in the open field arena without effect on locomotor activity. CONCLUSIONS AND IMPLICATIONS: L-29 produces analgesia in a range of neuropathic pain models. This presents L-29 as a novel analgesic compound that may target the endogenous cannabinoid system while avoiding undesirable side effects associated with direct cannabinoid receptor activation.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/sj.bjp.0707326

Cites

87 of 87 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • L29-induced suppression of thermal hyperalgesia was mediated by both the CB1 receptor and PPAR-α, whereas suppression of mechanical allodynia was mediated by CB1/CB2 and PPAR-α receptors.

    “The L29-induced suppression of thermal hyperalgesia was mediated by both the CB1 receptor and PPAR-α, whereas suppression of mechanical allodynia was mediated by CB1/CB2 and PPAR-α receptors.64”
  • L-29 suppressed thermal hyperalgesia and mechanical allodynia in the Seltzer model.

    “The fatty-acid analogue of PEA, L-29, also suppressed thermal hyperalgesia and mechanical allodynia in the Seltzer model.”
  • Approximately 50% of rats exposed to varicella-zoster virus developed mechanical allodynia in the ipsilateral paw by 14 days post-infection; no thermal hyperalgesia or cold allodynia was observed.

    “Approximately 50% of rats exposed to the varicella-zoster virus (VZV) developed mechanical allodynia in the ipsilateral paw by 14 days post-infection; no thermal hyperalgesia or cold allodynia was observed.64”
  • Neither a CB1- nor a CB2-specific antagonist suppressed L-29 mediated suppression of varicella-zoster virus-induced mechanical allodynia.

    “However, neither a CB1- nor CB2-specific antagonist suppressed L-29 mediated suppression of VZV-induced mechanical allodynia.64”
  • The PEA analogue L-29 suppressed mechanical allodynia in the varicella-zoster virus model with an earlier onset relative to gabapentin.

    “The PEA analogue L-29 suppressed mechanical allodynia in this model with an earlier onset relative to gabapentin.”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 2

  1. Rice ASC (2005). Cannabinoids. In: Melzack and Wall: Textbook of Pain. Elsevier: London, pp 521-540.
  2. Rice ASC, Lever I, Zarnegar R (2007). Cannabinoids and Analgesia, with Special Reference to Neuropathic Pain In: McQuay HJ and Moore RA (eds). IASP Press: Seattle, (in press).

Cited by

Sorted by citations

Authors
Wallace, V. C. J., Segerdahl, A. R., Lambert, D. M., Vandevoorde, S., Blackbeard, J., Pheby, T., Hasnie, F., & Rice, A. S. C.
Affiliations
  • Chelsea and Westminster Hospital (GB)
  • UCLouvain (BE)
Corresponding author
Rice, A S C
Venue
British Journal of Pharmacology
Publisher
Wiley
Published
2007-08
Volume
151
Issue
7
Pages
1117-1128
ISSN
  • 0007-1188 (ISSN-L)
  • 1476-5381
OpenAlex
W2165127221
Cited by
66
References
85
Citations by year
2024: 3 · 2023: 4 · 2022: 1 · 2021: 4 · 2020: 4 · 2019: 3 · 2017: 3 · 2016: 4 · 2015: 3 · 2014: 5 · 2013: 4 · 2012: 6
FWCI
3.58
Type
journal article
Language
en
Open access
Locations
  • British Journal of Pharmacology (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • DIAL (Catholic University of Leuven) (submittedVersion, other-oa)
Funders
  • Fonds De La Recherche Scientifique - FNRS
  • Fondation Charcot
Topics
  • Health Sciences › Medicine › Physiology › Pain Mechanisms and Treatments
  • Health Sciences › Medicine › Pharmacology › Cannabis and Cannabinoid Research
  • Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Treatment
Keywords
neuropathic pain, analgesia, endocannabinoid system, fatty acid amide hydrolase inhibition, CB1 receptor, CB2 receptor, PPARα, varicella-zoster virus, thigmotaxis, gabapentin
MeSH terms
Gabapentin, Rimonabant, Amides, Amines, Animals, Behavior, Animal, Camphanes, Chlorobenzenes, Cyclohexanecarboxylic Acids, Dose-Response Relationship, Drug, Ethanolamines, gamma-Aminobutyric Acid, Hindlimb, Indoles, Injections, Intraperitoneal, Male, Pain, Pain Measurement, Palmitic Acids, Physical Stimulation, Piperidines, Pyrazoles, Temperature, Zalcitabine, Rats, Wistar, Pain Threshold, Sciatic Neuropathy, Receptor, Cannabinoid, CB1, Receptor, Cannabinoid, CB2, PPAR alpha, Rats, Endocannabinoids

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review